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Targeting delivery of paclitaxel into tumor cells via somatostatin
receptor endocytosis
Chun-Ming Huang*, Ying-Ta Wu* and Shui-Tein Chen
Background: The binding of somatostatin (SST) to endogenous G-protein-
coupled receptors (SST receptors or SSTRs) is followed by internalization of SST,
and, several reports have shown that a high density of SSTRs is present on most
hormone-secreting tissue tumors. Facile synthesis of the long-acting SST analog,
octreotide, has previously been described. Octreotide might be of practical value
in developing tumor tracers and in serving as a carrier of cytotoxic antitumor drugs. 
Results: Fluorescein-labeled octreotide was internalized into the cytosol of
human breast MCF-7 carcinoma cells via binding to SSTRs. Octreotide-
conjugated paclitaxel (taxol) was created by coupling taxol–succinate to the
amino-terminal end of octreotide. This conjugate retains the biological activity
of taxol in inducing formation of tubulin bundles, eventually causing apoptosis
of MCF-7 cells. Cytotoxicity of octreotide-conjugated taxol is mainly mediated
by SSTR, as shown by the observation that octreotide pretreatment can
rescue the induced cell death. In comparison with free taxol, this conjugate
shows much less toxicity in Chinese hamster ovary cells.
Conclusions: Octreotide-conjugated taxol exerts the same antitumor effect of
free taxol on stabilizing microtubule formation and inducing cell death. This
conjugate triggers tumor cell apoptosis mediated by SSTRs and is exclusively
toxic to SSTR-expressing cells. Octreotide-conjugated taxol is less toxic to low-
SSTR-expressing cells compared with free taxol. Our results strongly indicated
that octreotide-conjugated taxol demonstrates cell selectivity and may be used
as a targeting agent for cancer therapy.
Introduction
Somatostatin (SST) is a neuropeptide that demonstrates a
powerful inhibitory action against several endocrine
systems. SST was originally isolated as an endocrine
inhibitor of pituitary growth hormone secretion and is now
recognized as a hormone capable of regulating fundamental
processes, such as secretion, cell division, proliferation and
apoptosis [1–3]. The cellular actions of SST are mediated
by a family of GTP-binding-protein-coupled receptors, of
which there are five (termed SSTR-1, -2, -3, -4 and -5) [4].
Most neuroendocrine tumors and their metastases express
SSTRs to a much greater extent than do normal tissues
[5–7]. The clinical usefulness of SST is limited, however,
by its very short half-life. For therapeutic feasibility in
humans, several synthetic SST analogs have been created
with improved metabolic stability. A significant milestone
in these efforts has been the design and synthesis of
octreotide (SMS 201-995, SandostatinTM), an octapeptide
analog of native SST [8]. This compound was found to be
more potent than native SST in suppressing the release of
growth hormone and to be more selective in its effects.
Since 1983, octreotide had been used therapeutically to
prevent carcinoid crisis [9] and used also in clinical practice
for the scintigraphic visualization of tumors containing a
high density of SSTRs [10]. Lamberts et al. [11] and Kren-
ning and co-workers [12] have demonstrated that radiola-
beled octreotide derivatives 123I–[Tyr3]-octreotide and
111In–diethylenetriamine penta-acetic acid (DTPA)
octreotide are very useful for detecting small neuroen-
docrine tumors that cannot be detected by conventional
means, and also for identifying tumors that respond to
therapeutic doses of octreotide. Previously, we have
described a facile synthesis of octreotide and its fluores-
cein-labeled derivative [13], which might serve as power-
ful tools for tumor identification. These promising results
prompted us to develop octreotide as a specific carrier to
deliver antitumor drugs, such as paclitaxel, into tumor cells
via SSTR endocytosis.
Paclitaxel (or Taxol [Bristol-Myers Squibb, Princeton, NJ])
is a diterpenoid taxane derivative, which was first isolated
from Taxus brevifolia by Wani et al. in 1971 (see [14] and ref-
erences therein). It shows excellent antitumor activity in a
wide variety of tumor models, such as B16 melanoma,
L1210 and P388 leukemias, MX-1 mammary tumor and
CX-1 colon tumor xenografts [15–17]. The antitumor prop-
erty of taxol is due to its ability to promote tubulin assembly
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into microtubules [18]. In the presence of taxol, micro-
tubules resist depolymerization, thus interfering with the
G2 and M phases of the cell cycle [19]. In spite of its excel-
lent antitumor activity, there are considerable difficulties in
developing taxol as a chemotherapeutic agent — one major
difficulty is that taxol is not cell specific.
In the present study, fluorescein-labeled octreotide is syn-
thesized and used to verify specific receptor binding activi-
ties. It was used also to trace the intracellular localization of
such activities. Simultaneously, we describe the synthesis
of taxol linked to octreotide by chemical conjugation. Using
MCF-7 and CHO cells as models, a comparison of cytotoxi-
city and cell specificity between taxol and octreotide-conju-
gated taxol was made. Our aim was to evaluate the role of
octreotide-conjugated taxol in SSTR-mediated internaliza-
tion and in tubulin binding followed by programmed cell
death, in low- and high-density SSTR-expressing cells.
Results and discussion
Effects of octreotide on cell viability of MCF-7 cells
MCF-7 human breast cancer cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) containing
1% bovine fetal serum in the absence or the presence of
the SST analog octreotide for one to seven days. Treat-
ment of octreotide for up to three days did not signifi-
cantly alter the rate of growth of MCF-7 cells (Figure 1).
However, octreotide inhibited proliferation of MCF-7
cells at treatment times of more than three days. This was
time- and dose-dependent — in the presence of
octreotide at increasing concentrations (10 nM, 100 nM
and 0.01 mM), a significant suppression of cell growth was
observed on day 7; the cell number had decreased by
80 ± 4.1%, 68 ± 6.2%, and 51 ± 2.1%, respectively, com-
pared with the controls (p <0.001). In agreement with pre-
vious findings [20–22], our results indicated that
octreotide, synthesized in our laboratory, is responsible for
this antiproliferative activity in MCF-7 cells. 
In contrast to the study by Sharma and Srikant [23], who
demonstrated that octreotide stimulates apoptosis in
MCF-7 cells by inducing wide-type p53, a tumor suppres-
sor protein, Bax and acidic endonuclease, octreotide syn-
thesized in our laboratory did not induce apoptosis in
MCF-7 cells (shown by observing the chromatin conden-
sation by electron microscopy and the Hoechst 33258
nuclear stain [data not shown]). The difference in the
findings could be due to the source of octreotide or to dif-
ferential expression of SSTR subtypes in MCF-7 cells cul-
tured in the different laboratories. In our laboratory, we
analysed apoptosis in MCF-7 cells by directly observing
cell ultrastructure using electron microscopy, rather than
flow-cytometric measurement, which was used by Sharma
and Srikant [23]. As stated earlier the different results
might be explained further by determining SSTR sub-
types expressed in MCF-7 cells cultured in our laboratory.
To this aim, the reverse transcription polymerase chain
reaction (RT-PCR) will be performed in future studies,
using primers for individual SSTRs. 
Five distinct SSTRs have been cloned from humans, mice
and rats and classified on the basis of their ability or inabil-
ity to bind octapeptide SST analogs [24] into distinct sub-
families; one comprising SSTR-2, -3 and -5, the other
SSTR-1 and -4. Cyclic hexapeptide and octapeptide SST
analogs bind to the first group, (SSTR-2, -3 and -5), but
not to SSTR-1 and -4. MCF-7 cells have been shown to
express SSTR-1, -2, -4 and -5 but not SSTR-3 [25]. It is
likely, therefore, that the antiproliferative action of
octreotide is mediated through SSTR-2 or -5 or both. SST
induces apoptosis uniquely through human SSTR-3 [26].
In Chinese hamster ovary K-1 (CHO-K1) cells, this
SSTR-3-induced apoptosis is characterized by the appear-
ance of oligonucleosomal DNA and is associated with the
induction of wild-type (wt) p53 and Bax [26]. As MCF-7
cells do not express SSTR-3, however, the SSTR-3-medi-
ated apoptotic effects of octreotide could not be expressed
in these cells cultured in our laboratory.
Internalization of fluorescein-labeled octreotide in MCF-7
cells
Previously, radiolabeled octreotide was used for imaging
SSTR-positive tumors through the binding of octreotide
454 Chemistry & Biology 2000, Vol 7 No 7
Figure 1
Effect of octreotide on cell growth. MCF-7 cells were treated with 10 nM
(l), 100 nM (n) or 0.01 mM (s) octreotide for seven days. Long-term
(i.e. more than three days) treatment of octreotide exerts an inhibitory
effect on cell growth. Data are mean ± SE (bars) values from three
independent experiments. *p <0.01, †p <0.001, compared with control
cells (without octreotide treatment at 0 day) using student’s t test.
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to an SSTR [27]. Fluorescein-labeled octreotide presents
a relatively safe way to visualize the interaction between
octreotide and an SSTR. We successfully synthesized flu-
orescein-labeled octreotide using p-carboxybenaldehyde
as a linker by which to anchor fluoren-9-ylmethoxycar-
bonyl (Fmoc)-throneninol to solid-phase resins, and then
fluorescein in the final coupling cycle. 
Although octreotide is a peptide-based drug, it has remark-
able stability in the presence of degradative enzymes
(compared to native SST) [28]. It is expected that
octreotide will not be degraded in incubation medium con-
taining bovine fetal serum. Observations thereafter can
ignore effects caused by octreotide degradation in
medium. In agreement with this, high-performance liquid
chromatography (HPLC) analysis demonstrated that
octreotide and fluorescein-labeled octreotide were not
degraded after 24 h of incubation in DMEM containing
1% bovine fetal serum (data not shown). In order to evalu-
ate whether octreotide demonstrates specific targeting in
SSTR- expressing cells, we analysed the binding of fluo-
rescein-labeled octreotide in two cell lines: MCF-7 cells
(presenting high-affinity binding sites for octreotide) and
CHO cells (which express low levels of SSTR
[196 fmol/mg protein]) [29]. Incubation of MCF-7 cells
with fluorescein-labeled octreotide (100 µg/ml) at 4°C for
30 min resulted in a specific but diffusely distributed fluo-
rescein along the cell surface of MCF-7 cells
(Figures 2a,b), whereas upon incubation at 37°C for 10 min
under parallel conditions, denser fluorescent grains were
visible mainly at the cell periphery (Figure 3a,b). At 1 h
(Figure 3c,d), fluorescent grains were distributed through-
out the cytosol of the cell and many grains were clustered
at the periphery of cell nucleus. These results suggest that
this octreotide conjugate binds SSTR and then is internal-
ized via SSTR-mediated endocytosis in MCF-7 cells. Flu-
orescence is no longer apparent in MCF-7 cells pretreated
with 1000-fold excesses of unlabeled octreotide for 1 h at
4°C (Figure 2c,d) or 37°C (Figure 3e,f). 
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Figure 2
(b,d,f,h) Fluorescence micrographs of MCF-7 and CHO cells after
incubation with 100 µg/ml fluorescein-labeled octreotide at 4°C for
30 min. (b) The labeling is confined to the MCF-7 cell surface.
(d) The labeling is no longer apparent in MCF-7 cells incubated in the
presence of an excess of nonfluorescent octreotide (100 mg/ml).
(f) No labeling was seen in CHO cells, even in cells incubated with
500 µg/ml fluorescein-labeled octreotide (h). (a,c,e,g) Cell
morphologies under the associated conditions.
Figure 3
Confocal microscopic imaging of internalized fluorescein-labeled
octreotide in MCF-7 cells. (a,b) After 10 min of incubation with
100 µg/ml fluorescein-labeled octreotide at 37°C, fluorescent labels
are mainly apparent at periphery of the cell (arrowheads). (c,d) At 1 h,
most label is clustered around the nucleus (arrows). (e,f) No
fluorescence was seen in cells incubated with 100 mg/ml octreotide
(without fluorescein tag) for 1 h prior to incubation with fluorescein-
labeled octreotide for 10 min. 
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No labeling was seen in CHO cells when incubated with
100 µg/ml or 500 µg/ml of fluorescein-labeled octreotide
(Figure 2f,h). These results indicate that octreotide is a
powerful drug carrier to deliver the drugs into SSTR-
expressing cells. 
To develop novel, targeted antitumor agents for the treat-
ment of various cancer-cell-expressing receptors for SST, we
conjugated octreotide to taxol, a diterpenoid plant product,
and demonstrated its superior antitumor activity by binding
preferentially to the amino-terminal region of the β-tubulin
subunit of microtubule polymers. Taxol is an effective drug
that shows efficacy in human ovarian and metastatic breast
cancers [30,31] and malignant melanoma [32]. The molecu-
lar mechanisms underlying taxol-induced apoptosis of
MCF-7 cells have been studied. Such mechanisms studied
include p34cdc2 kinase activation [33], and p21Waf1 and p53
induction [34]. The role of taxol in combating certain
cancers and our current understanding of the underlying
mechanisms make it a good candidate for an antitumor drug
linked to octreotide. The cell specificity of the antitumor
effect of taxol is low, so it is highly toxic in most human cells
when a cancer patient is treated with taxol-based
chemotherapy [16,17]. The design of taxol linked to a tumor
tracer, such as octreotide, may be employed to enhance the
cell specificity and selectivity of taxol. 
Design and synthesis of octreotide-conjugated taxol
The design for synthesis octreotide-conjugated taxol was
based on the properties of SSTR endocytosis when
octreotide binds to SSTR. Octreotide-conjugated taxol
internalization into the cytosol of SSTR-expressing tumor
cells could decrease the cytotoxicity of taxol in non-SSTR-
expressing cells. When designing such a conjugate, we
sought to retain the binding properties of the carrier
peptide, as well as the antitumor activity of taxol. First, flu-
orescein-labeled octreotide was synthesized in order to test
its SSTR binding properties (described above).
Structure–activity studies on taxol revealed that the C-13
ester sidechain and its 2′-hydroxl group appear essential for
tubulin binding [35,36]. The observation therefore suggests
that the 2′ and 7′ position are suitable sites for reversible
derivatization [37,38]. The creation of taxol-conjugated
octreotide is depicted in Figure 4. Taxol-succinate (2′-suc-
cinyl-paclitaxel) was synthesized by following the proce-
dure described by Deutsch et al. [37], and was activated by
benzotriazol-1-yloxy-tris-pyrrolidinophosphonium (PyBOP)
in dimethyl formamide (DMF) before being coupled to the
α amino group at the amino terminus of octreotide, which
was bound to Siber amide resin. Octreotide (NH2-D-
Phe–c[Cys–Phe–D-Trp–Lys(Mtt)–Thr–Cys]–Thr-ol-acetal;
Mtt, 4-methyltrityl), was synthesized to Siber amide resin
using solid-phase Fmoc chemistry, followed by on-resin
disulfide formation after oxidation by thallium(III)-trifluo-
roacetate in DMF at 0°C for 80 min [13,39]. 
It has been pointed out that the taxol molecule is fragile in
strongly acidic conditions and no pure product could be iso-
lated after a standard acidic cleavage and deprotection
[37,38]. Siber amide resin, which has an acid-sensitive
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Figure 4
Molecular structure of octreotide-conjugated
taxol. Paclitaxel succinate is conjugated to the
amino terminus of octreotide. (a) Paclitaxel
and succinic anhydride are dissolved in
pyridine and stirred for 3 h. (b) Paclitaxel
succinate is activated by PyBOP in DMF and
reacted with the amino terminus of octreotide.
(c) The peptide conjugate is deprotected and
cleaved from the amide resin by addition of
1% TFA/DCM; compounds are neutralized
using 15% pyrinidine in methanol before
purification using HPLC.
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linker, was therefore used as the solid support to avoid the
strong acidic conditions of trifluoroacetic acid (TFA) cleav-
age and to prevent the taxol molecule from being damaged.
Biological properties of octreotide-conjugated taxol
To investigate whether octreotide-conjugated taxol
retains the biological properties of taxol [40], we treated
MCF-7 cells with 10–6 M taxol and with octreotide-con-
jugated taxol for 8 h. The change in microtubules was
visualized by indirect immunofluorescent staining using
β-tubulin antibody (Figure 5a–c). Cell morphology is
thought to be maintained by the cytoskeleton; reorgani-
zation of the cytoskeletal networks was therefore
explored using fluorescence microscopy. It was found
that, after an 8 hour treatment with 10–6 M taxol or
octreotide-conjugated taxol, MCF-7 cells showed exten-
sive clustering of tubulin around nuclei (Figure 5b,c).
Tubulin bundles were visualized in orange (intensive
rhodamine staining) and quantified by counting over 800
cells. In the presence of taxol or octreotide-conjugated
taxol (10–6, 10–5 and 10–4 M), the percentages of cells
containing tubulin bundles were 67%, 83% and 92%,
respectively, for taxol treatment, and 65%, 81% and 93%,
respectively, for octreotide-conjugated taxol treatment
(data not shown). Octreotide-conjugated taxol and taxol
were therefore equally active regarding microtubule
bundle formation. 
Understanding the properties of these two drugs with
respect to induction of apoptosis was also of interest. We
distinguished between viable and apoptotic cells on the
basis of cellular nuclear chromatin pattern, which was
assessed by fluorescent microscopic analysis of nuclei
stained with Hoechst 33258 (Figure 5g–i), and by electron
microscopy (Figure 5d–f). The nuclear chromatin of viable
MCF-7 cells was dispersed, whereas that of apoptotic cells
was condensed into densely fluorescent apoptotic nuclear
fragments. We have found that both drugs can induce
chromatin condensation after 24 h treatment (Figure 5e,f),
and from observations using electron microscopy, we also
have found that the nuclear membrane disappeared after
treatment with both taxol and octreotide-conjugated taxol
under these conditions. Both drugs induce p34cdc2 kinase
activation, which controls the G2 to M phase transition by
promoting breakdown of the nuclear membrane and chro-
matin condensation [29,33,41]. 
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Figure 5
Octreotide-conjugated taxol virtually retains the cellular functions of
taxol. (a,b,c) Distribution of β tubulin in MCF-7 cells. Cells were (a) in
the absence of both taxol and octreotide-conjugated taxol (b) the
presence of 10–6 M taxol or (c) octreotide-conjugated taxol.
(d–i) Chromatin condensation in apoptotic cells. (d–f) Ultrastructure of
apoptotic MCF-7 cells as observed using transmission electron
micrography (×7500). (g–i) Nuclei were stained with Hoechst 33258
and fluorescence photomicrographs were taken. MCF-7 cells were
treated without (d,g) or with 10–6 M taxol (e,h) or octreotide-
conjugated taxol (f,i) for 24 h. Arrows indicate chromatin condensation
in apoptotic cells. 
Figure 6
Pretreatment with octreotide antagonizes the cytotoxicity of octreotide-
conjugated taxol, but treatment with taxol alone does not. MCF-7 cells
were pretreated with 10–2 M octreotide (Oct) for 30 min prior to
treatment with 10–5 M taxol, or octreotide-conjugated taxol (Oct/Taxol)
for 24 h. Data are mean ± SE (bars) values from three separate
measurements, using three different batches of cells. 
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Figure 5 therefore illustrates clearly that octreotide-con-
jugated taxol retains the ability of taxol to bind β-tubulin
subunits of microtubule polymers and to trigger apopto-
sis of MCF-7 cells.
To determine whether octreotide-conjugated taxol causes
cytotoxicity via association with SSTRs, we pretreated
MCF-7 cells with 10–2 M octreotide for 1 h prior to treat-
ment of 10–5 M octreotide-conjugated taxol or taxol alone
for 24 h (Figure 6). Treatment for 24 h with octreotide alone
did not affect the cell viability significantly (see Figure 1).
However, after treatment with 10–5 M octreotide-conju-
gated taxol or free taxol for 24 h, cell viability was 46 ± 2.7%
and 41 ± 3.3% compared with controls. Pretreatment with
10–2 M octreotide resulted in a significant increase in viabil-
ity (77 ± 6.2%) of MCF-7 cells that are treated with
octreotide-conjugated taxol for 24 h. Pretreatment of
octreotide therefore antagonizes the cytotoxicity of
octreotide-conjugated taxol. However, pretreatment of
octreotide cannot antagonize the cytotoxicity of taxol.
Owing to the hydrophobic nature of taxol, it has been sug-
gested that taxol is transported across membranes by passive
diffusion [42]. Our results show that, unlike free taxol,
octreotide-conjugated taxol causes cytotoxicity mainly
mediated by the endocytosis of SSTR. Octreotide-conju-
gated taxol, performed by coupling succinylated taxol to the
amino terminus of octreotide, seems not to be degraded
until it is internalized into the cytosol of MCF-7 cells.
Cell-specific differences in cytotoxicity of octreotide-
conjugated taxol
Antiproliferative activities of taxol and octreotide-conju-
gated taxol were evaluated in MCF-7 and CHO cells.
Drug concentrations that inhibited cell growth by 50% are
presented as IC50 values, and taxol had IC50 values of 10–7
and 10–6 M in MCF-7 and CHO cells, respectively
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Figure 7
Cell specificity of octreotide-conjugated taxol.
(a) Like free taxol (l), octreotide-conjugated
taxol (n) induced dose-dependent cell death
in MCF-7 cells at 1, 10, 100, 1000 and
10,000 nM. Data of treatments with higher
concentrations were not shown due to
precipitation in cell media. (b) Unlike free
taxol, octreotide-conjugated taxol is
significantly less toxic in CHO cells. MCF-7
(c–e) and CHO (f–h) cells were treated with
10–5 M taxol (d,g) or octreotide-conjugated
taxol (e,h) for 24 h. Cell death was indicated
by arrows. Data are mean ± SE (bars) values
of five separated measurements, using five
different batches of cells experiments.
0 1 10 100 1000 10000
Concentration (nM)
0 1 10 100 1000 10000
Concentration (nM)
C
el
l v
ia
bi
lit
y 
(%
 c
on
tr
ol
)
120
110
100
90
80
70
60
50
40
30
20
10
0
(c) (f)
(a) (b)
(d) (g)
(e) (h)
Chemistry & Biology20 m m
MCF-7 CHO
cm7711.qxd  07/03/2000  01:02  Page 458
(Figure 7). Both drugs caused precipitates in cell media at
concentrations higher than 10–5 M, and cell growth
remained at the same lowest level; thus Figure 7 does not
show the results of treatments at higher concentrations. 
In agreement with earlier findings [42], species-specific
differences in taxol cytotoxicity against human and
rodent tumor cells could result from the presence of dif-
ferent taxol transport systems. The octreotide-conjugated
taxol, which is slightly less toxic than taxol, induced
dose-dependent cell death in MCF-7 cells. Unlike taxol
alone, the cytotoxicity of octreotide-conjugated taxol is
much lower in CHO cells. These results suggest that
cells that express low levels of SSTRs (e.g. CHO cells)
are highly resistant to octreotide-conjugated taxol. More-
over, octreotide-conjugated taxol induces cell death in a
cell-specific manner — that is, exclusively in cells
expressing high levels of SSTRs. 
Significance
Most cytotoxic antitumor drugs suffer from a common
problem: toxic side effects due to a lack of drug selectiv-
ity. The antiproliferative effects of chemotherapeutic
agents such as mitomycin C, doxorubicin, 5-fluorouracil
and taxol are synergistically enhanced by co-treatment
with octreotide in vitro and in vivo [43]. However, when
doxorubicin or its superactive derivative, 2-pyrrolino-
doxorubicin, are linked chemically to the analogs of
somatostatin (SST), octapeptides RC-160 and RC-121
[44], the cytotoxicity of doxorubicin or 2-pyrrolinodox-
orubicin is decreased or maintained at the same level in
various tumor cell lines. Therefore, using endocytotic
ligands as carriers of the anticancer drugs to target these
drugs to the cancer cells, these toxic side effects can be
dramatically decreased and the efficacy of these drugs
greatly improved. In previous studies [45], octreotide
proved to be more potent in inhibiting the secretion of
growth hormone and to have a longer plasma half life
than native SST. Therefore, it is a particularly desirable
peptide for development as a targeted antitumor drug.
Moreover, the high-level expression of SSTRs on
various tumor cells compared with normal tissue or
blood affords its successful use as a tumor tracer.
Octreotide D-Phe–c[Cys–Phe–D-Trp–Lys–Thr–Cys]–
Thr-[ol] labeled with fluorescein is a powerful tool to
visualize tumors that express SST receptors and can be
predictive in determining whether a patient should
receive SST octapeptide hormone therapy. 
Octreotide-conjugated taxol retains taxol’s ability to
induce apoptosis (Figure 8) via binding the β-tubulin
subunit of microtubule polymers. Octreotide-conjugated
taxol, but not free taxol, is toxic exclusively to tumor
cells expressing SSTRs. Therefore, it may prove highly
valuable to develop octreotide-conjugated antitumor
drugs.
Materials and methods
Materials
Fmoc amino acids, Rink AM resin, Siber amide resin and PyBOP
were purchased from Novobiochem (San Diego, CA). Fmoc-Thr-(ol)-
benzo-acetal was prepared previously in our laboratory [13]. Triiso-
propylsilane (TIS) was purchased from Acros, NJ. MCF-7 cells were
obtained from the American Type Culture Collection (Rockville, MD).
DMEM, fetal bovine serum, L-glutamine, penicillin (19 000 units),
streptomycin (10 mg/ml) and trypsin, EDTA (10×; 0.5%
trypsin–5.3 mM EDTA) were purchased from Gibco BRL Life Tech-
nologies (Grand Island, NY). Taxol was obtained from Hauser Inc.
(Boulder, CO, USA). Taxol was dissolved in 95% ethanol before
being diluted into incubation medium immediately before experi-
ments. Bisbenzimide trihydrochloroacetic acid (Hoechst 33258,) and
MTT (3-[4,5-dimethylthiazol-2,5]-diphenyl tetrasolium bromide) were
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Figure 8
The octreotide-conjugated taxol serves as a targeted antitumor drug
for treatment of various tumors expressing SSTRs. Octreotide-
conjugated taxol causes cytotoxicity mainly mediated by the
endocytosis of SSTR. It induces cell death exclusively in cells
expressing high levels of SSTRs. Bz, benzoyl; Ac, acetyl.
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obtained from Sigma Chemical Co. (St. Louis, MO). All other chemi-
cals were obtained from Merck (Darmstadt, Germany).
Cell culture
MCF-7 breast tumor cells were maintained in DMEM supplemented
with glutamine (0.292 mg/ml), penicillin/streptomycin (0.5 ml/100ml
medium), 1% bovine fetal serum at 37°C under 5% CO2. The medium
was changed every two to three days. To assay of cell survival, the via-
bility was measured used trypan blue exclusion and MTT assay kit [46].
Synthesis of fluorescein-β-alanine-octreotide
Four equivalent of 5(6)-carboxy-fluorescein (0.4 mmole) were coupled to
the amino terminus of the assembly chain of NH2-β-Ala-D-Phe–c[Cys–
Phe–D-Trp–Lys(Mtt)–Thr–Cys]–Thr-ol-acetal-amide resin (0.1 mmol)
[13]. The coupling reaction was conducted in an aluminum-foil-wrapped
vessel. Direct light exposure was avoided thereafter. Cleavage of the
peptide conjugate from the amide resin was achieved using 95%
TFA/5% TIS. After evaporation of TFA under vacuum, the residue was
washed and precipitated by addition of ice-cold dry ether. The precipi-
tate was filtered on a sintered glass funnel and extracted using 20%
acetic acid solution. After lyophilization, the product was loaded onto a
Vydac C18 preparative column (Hesperia, CA) and purified. Electro-
spray ionization mass spectrometry (ESI–MS) result gave
[M+H]+ mass/charge (m/z) value of 1448 Da. 
Synthesis of paclitaxel succinate
Paclitaxel succinate was synthesized by following the procedure
described by Deutsch et al. [37]. Paclitaxel (0.43 g, 0.5 mmol) and
succinic anhydride (0.6 g, 6 mmol) were dissolved in 10 ml of pyri-
dine and stirred at room temperature for 3 h. At the end of the reac-
tion, the solution was evaporated to dryness in vacuo. The residue
was treated with 20 ml ice-cold water, stirring for 20 min, and filtered.
The precipitate was redissolved in acetone and then water was
added to produce fine crystals of paclitaxel succinate (0.42 g with an
86% yield). ESI–MS gave [M+H]+ m/z 954 Da 
Synthesis of paclitaxel-succinyl–octreotide
The expected compound and synthetic procedure is illustrated in
Figure 4. Four equivalents of paclitaxel succinate activated by PyBOP
in DMF were added to resin-bound octreotide (0.1 mM) [39]. The end
of the reaction (i.e. binding of pacilitaxel succinate to the amino termi-
nus of octreotide) was monitored by the ninhydrine test, which mea-
sured loss of the free amino group at amino terminus of
lysine-protected octreotide. Cleavage and sidechain deprotection of
the peptide conjugate from the amide resin was achieved using 1%
TFA/5% TIS/dichloromethane (DCM). Compounds were neutralized
using 15% pyridine/methanol. The sample was lyophilized to 135 mg
crude product (69% crude yields). HPLC analysis was performed
with a Vydac C18 column (10 × 250 mm) with the eluent system:
30% B in A (A: 5% acetonitrile (ACN)/95% H2O/0.1% TFA;
B: 95% ACN /5% H2O/0.1% TFA) to 90% B with a linear gradient
for 30 min. The compound with a retention time of 10.1 min (~34%
purity calculated from the peak area) was isolated and analysed to
give [M+H]+ values of 1954 Da using ESI–MS. 
Morphological determination of levels of apoptosis
Morphological determination of levels of apoptosis was preformed by
labeling the cells with the nuclear strain Hoechst 33258 and visual-
ization by fluorescence microscopy [47]. Transmission electron
microscopy was also used to observe apoptotic cells [48]. Cells
were fixed in cold 4% glutaraldehyde in 0.1 M cacodylate buffer
(pH 7.4) at 4°C, dehydrated in grade acetone, passed through propy-
lene oxide, and embedded in EMbed-812 (Purchased from EMS, Fort
Washington, PA). Ultra-thin sections were cut and stained with uranyl
acetate and alkaline bismuth subnitrate and viewed under a Siemens
Elmiskop 102 electron microscope at 80 kV.
Fluorescence microscopy for β tubulin
Coverslips were coating with fetal bovine serum at 37°C for 30 min. Cul-
tured MCF-7 cells on coverslips were fixed by 2% formaldehyde. Fixed
cells were washed with Dulbecco’s phosphate buffered saline (PBS) for
5 min at room temperature and then permeabilized by acetone at –20°C
for 3 min. The permeabilized cells were then stained with anti-β-tubulin
antibody (1:200) in the presence of 1% (w/v) bovine serum albumin
(BSA) for 1 h. Cells were washed twice, for 10 min each time, with PBS
and then incubated with rhodamine-conjugated goat antimouse
immunoglobulin (1:200) for 1 h. The stained cells were mounted in 50%
(v/v) glycerol in PBS for observation by fluorescence microscope.
Confocal microscopy
Cells were incubated with fluorescein-labeled octreotide in PBS buffer
containing 2 mM MgCl2 and 0.1 % BSA. Labeled cells were examined
under a Zeiss LSM 310 microscope configured with a Axioplan
equipped with an argon laser.
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